BeOne Medicines (ONC) SVP Henry exercises options and sells 1,660 ADS

Rhea-AI Filing Summary

BeOne Medicines Ltd. SVP and general counsel Lee Chan Henry reported option exercises and share sales. On 02/04/2026, Henry exercised three employee share options covering 6,526, 8,606 and 6,448 ordinary shares, which relate to American Depositary Shares (each ADS represents 13 ordinary shares).

On the same date, Henry sold 664 ADS at $348.79 and 996 ADS at $350.00 under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025, leaving no ADS directly held. Henry continues to directly hold 223,106 ordinary shares and significant remaining options that vest over multi-year schedules, subject to continued service and potential accelerated vesting on certain termination events.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Chan Henry

(Last) (First) (Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL V8 4051

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares								223,106	D
American Depositary Shares(1)	02/04/2026		M		502	A	$194.47	502	D
American Depositary Shares(1)	02/04/2026		M		662	A	$213.32	1,164	D
American Depositary Shares(1)	02/04/2026		M		496	A	$159.03	1,660	D
American Depositary Shares(1)	02/04/2026		S(2)		664	D	$348.79	996	D
American Depositary Shares(1)	02/04/2026		S(2)		996	D	$350	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$14.96(3)	02/04/2026		M			6,526	(4)	08/04/2032	Ordinary Shares	6,526	$0	23,920	D
Share Option (Right to Buy)	$16.41(3)	02/04/2026		M			8,606	(5)	06/14/2033	Ordinary Shares	8,606	$0	88,413	D
Share Option (Right to Buy)	$12.23(3)	02/04/2026		M			6,448	(6)	06/04/2034	Ordinary Shares	6,448	$0	111,670	D

Explanation of Responses:

1. Each American Depositary Share represents 13 Ordinary Shares.

2. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025.

3. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.

4. These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

5. These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

6. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did BeOne Medicines (ONC) report for Lee Chan Henry?

BeOne Medicines reported that SVP and general counsel Lee Chan Henry exercised multiple share options into ordinary shares and corresponding ADS, then sold 1,660 American Depositary Shares on February 4, 2026, in two trades, as disclosed in a Form 4 insider transaction filing.

How many BeOne Medicines ADS did Lee Chan Henry sell, and at what prices?

Lee Chan Henry sold a total of 1,660 American Depositary Shares. The sales were 664 ADS at $348.79 and 996 ADS at $350.00, all executed on February 4, 2026, according to the reported non-derivative transactions in the insider filing.

Were Lee Chan Henry’s BeOne Medicines share sales under a Rule 10b5-1 plan?

Yes. The filing states the ADS sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Lee Chan Henry on May 14, 2025. Such plans pre-schedule trades, providing a structured framework for selling shares over time.

What BeOne Medicines derivative securities did Lee Chan Henry exercise?

Lee Chan Henry exercised three “Share Option (Right to Buy)” grants on February 4, 2026, covering 6,526, 8,606 and 6,448 ordinary shares. These options had exercise prices represented in ordinary shares and relate to equity awards that vest over four-year schedules.

How many BeOne Medicines ordinary shares does Lee Chan Henry hold after these transactions?

Following the reported transactions, Lee Chan Henry directly beneficially owns 223,106 ordinary shares of BeOne Medicines. The filing also shows remaining option positions, with derivative securities beneficially owned totaling tens of thousands of underlying ordinary shares.

What is the ADS to ordinary share ratio for BeOne Medicines (ONC)?

Each BeOne Medicines American Depositary Share represents 13 ordinary shares. This means ADS amounts reported in the filing correspond to a larger number of underlying ordinary shares, as explicitly stated in the footnotes to the insider transaction report.